LLMs can speed up evidence work. But if you can’t reproduce and audit what the model changed, your “AI-enabled” pipeline can become a credibility liability.

**Advanced Therapy (ATMP) projects often fail from poor decision-making, not weak science. FRESCI tackles this bottleneck by structuring uncertainty, aligning evidence with strategic goals, and applying proactive regulatory science. Our focus: smarter decisions and clear thinking to navigate ATMP complexity and translate scientific potential into approved, accessible therapies.

The Imperative of Market Viability/Economic sustainability In the rapidly evolving field of scientific research, particularly in...

In the ever-evolving field of health research, there lies a complex interplay between technological standardization, market acceptance,...

The biomedical research landscape is evolving at breakneck speed, ushering in an era of precision, accuracy, and human-centric...

Creation of an open cross-disciplinary environment for diverse communities in biomedical sciences to discuss their methods and...

Have you read our project report yet? Check out the final results of our European Project with DG. JRC (EURL - ECVAM) on human-based...

Suggested reading!

COVID-19: FRESCI helps researchers and startups in this crisis....this is an example.

DIVING INTO THE SCIENTIFIC KNOWLEDGE BIG DATA LOOKING FOR ALTERNATIVES This is the workshop session that FRESCI is organising at the 11th...